Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK)

@article{MatterWalstra2016PalbociclibAA,
  title={Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK)},
  author={K Matter-Walstra and Thomas Ruhstaller and Dirk Klingbiel and Matthias Schwenkglenks and Konstantin Johannes Dedes},
  journal={Breast Cancer Research and Treatment},
  year={2016},
  volume={158},
  pages={51-57}
}
Endocrine therapy continues to be the optimal systemic treatment for metastatic ER+HER2− breast cancer. The CDK4/6 inhibitor palbociclib combined with letrozole has recently been shown to significantly improve progression-free survival. Here we examined the cost-effectiveness of this regimen for the Swiss healthcare system. A Markov cohort simulation based on the PALOMA-1 trial (Finn et al. in Lancet Oncol 16:25–35, 2015) was used as the clinical course. Input parameters were based on summary… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 4 times. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-6 OF 6 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 25 REFERENCES

Similar Papers

Loading similar papers…